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Parvovirus B-19 infection during pregnancy
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The development of an acute parvovirus B-19 infection during pregnancy can cause pregnancy complications
ranging from early pregnancy loss to nonimmune hydrops. There is no treatment, but preventive measures can be
usedtodecreaseperinatalmortality.Thediagnosisismadeonthebasisofclinicalsuspicionandserology.Ifthefetus
exhibitshydropsinthelatterpartofpregnancy,themaintreatmentoptionsincludeeithercorrectingtheassociated
anemiawithintrauterinebloodtransfusionorbirthwithextrauterinemanagement.Althoughtheseriousproblems
associated with this virus during pregnancy are uncommon, they can be fatal. In view of this, a pregnant woman
who is antibody negative should try to avoid contact with large groups of young children in order to decrease
contact with potential vectors.
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Parvovirus B-19is an endemic viral infection that
is most frequently seen among preschool and
school-age children in the USA. B-19has histori-
cally been referred to as ‘slapped cheek’ disease or
theFifthdisease,becauseitwasthefifthdiseasethat
was found to cause rash in children (the first four
being measles, scarlet fever, rubella and Duke’s
disease; exanthem subitum is the sixth)1. Cossart
et al.2 discovered parvovirus B-19in 19 74. While
screening for the hepatitis B infection, they were
obtaining false-positive results. When these
particles were studied, it was found that they were
infactaparvovirus.ThespecificationasB-19arose
from the fact that the positive virus was found in
thespecimenthatwasonpanelBandspecimen19.
Soon afterwards, Anderson et al.3 reported that
parvovirus B-19 was the cause of Fifth disease.
Parvovirus B-19is a linear, nonenveloped,
encapsulated, icosahedral, single-stranded DNA
virus with a terminal hairpin structure that forms a
double-stranded section characteristic of the
Parvoviridae family4. Parvovirus has been found in
individuals of all ages, but the highest incidence
of the virus is in patients aged 5 to 15 years.
PATHOGENESIS
Parvovirus B-19is the only parvovirus that is
known to cause disease in humans. Another
parvovirus, dependovirus, has been isolated in
humans. However, it is not believed to cause
illness, and is only thought to infect humans when
it is associated with an adenovirus5.
Cytological properties that are characteristic of
parvovirus B-19infection include giant pro -
normoblasts, cytoplasmic vacuolization, immature
chromatin and large eosinophilic nuclear inclusion
bodies4. The virus has a predilection for rapidly
multiplying erythroid progenitor cells. This is
explained by the presence of the virus receptor,
globoside. Globoside, or blood group P antigen, is
mainly found on the erythroid progenitor cells,
erythroblasts and megakaryocytes. It is thought to
be the cellular receptor for parvovirus B-196.
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subjects to parvovirus B-19and studied its effects.
They described what is now known as the classic
biphasic parvovirus B-19presentation. There is an
average 6-day incubation period, after which the
first phase of the disease begins with viremia,
shedding of viral particles, erythroid-progenitor-
cell depletion and parvovirus B-19-specific IgM
antibodies. Virus particles can be found in nasal
washes and gargles, but not in the urine. This is
the period of transmissibility, and it is usually
asymptomatic. However, patients may experience
a nonspecific prodromal illness characterized by
fever, malaise, myalgias, headache and pruritus.
About 1 week into phase 1, the pediatric
patient may present the classic ‘slapped cheek’
appearance.Phase2beginsabout17 daysafterviral
exposure, and is characterized by the appearance
of parvovirus B-19-specific IgG antibodies and
a corresponding decreasing viremia. The patient
may experience joint stiffness that usually
resolveswithinafewweeks4.Later,alaceyerythe-
matous rash may develop on the trunk and
extremities.
Although parvovirus B-19is mainly considered
to be a childhood disease, adults may also be
infected. However, it is rare for adults to develop a
rash. Instead, B-19is better known for causing an
aplastic crisis in adults with an underlying chronic
anemia. This aplastic anemia is caused by the
preference of B-19for the rapidly multiplying
erythroid progenitor cells7.
Parvovirus B-19can also cause persistent
arthralgias. Studies have reported that arthropathy
occurs in 60% of adults and less than 10% of
children8–10. Most commonly the arthritis starts in
the hands, knees, wrists and ankles. Most cases of
B-19arthropathy subside within 1 to 3 weeks.
However, B-19is probably an underdiagnosed
cause of arthritis, as evidenced by a study in which
12% of patients in an arthritis clinic tested IgM
positive11.Thisismuchhigherthanthefigureseen
in the general population, and it suggests that a
chronic parvovirus B-19infection is the cause of
many cases of arthritis.
Research has been undertaken to determine
whether a correlation exists with regard to an
increase in parvovirus B-19in patients with blood
transfusions. It was found that of 100 previously
B-19-antibody-negative patients, 18 individuals
seroconverted to antibody-positive within 3
months of the transfusion. Although this disease
may not be very harmful to a healthy nonpregnant
woman, it is of considerable significance to those
who are pregnant. In the follow-up study, the
seroconversionwasreducedtozerowiththeuseof
additional screening for parvovirus and discarding
of seropositive blood products12.
EFFECT OF PARVOVIRUS B-19 IN
PREGNANCY
It has been noted that 3–19% of pregnant women
will serologically convert to IgM positive on
exposure to parvovirus B-19, with a 33% vertical
transmission rate13. Although the virus can be
contracted in any trimester, the second trimester
seems to carry the highest risk of fetal loss. It has
also been noted, without a cause-and-effect
relationship having been proven, that there is a
2–3% incidence of this virus in all spontaneous
abortions14.
Prospective studies of pregnant women have
found that if the patient was susceptible to parvo-
virus B-19infection, her fetuses might suffer from
especiallyprofoundsequelae,suchasfetalhydrops,
anemia and even potential fetal demise. These
studiesdidnotfindanyincreaseintheincidenceof
congenital malformations due to parvovirus
B-1915. A retrospective study of 300 babies with
congenital anomalies found that the incidence of
B-19was no higher than in healthy infants. This
has led us to believe that B-19toxicity is
embryologic rather than teratogenic14.
The risk of fetal demise is highest in the first
trimester, and is thought to be as high as 10% in
women who are infected prior to 20 weeks’ of
gestation16. In a patient with a history of previous
miscarriage due to parvovirus, the antibodies to
B-19will still be present during her next preg -
nancy, but there is no increase in the likelihood
of miscarriage in the second pregnancy due to
these antibodies17. B-19is toxic not only to the
maternal red-blood-cell precursors but also to fetal
red-blood-cell precursors. Destruction of fetal red
blood cells can lead to nonimmune hydrops
fetalis. The risk of fetal hydrops is substantial, at
around 3%17.
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and since then many cases have been reported18.
Hydrops can develop within 2 weeks, and may
either resolve spontaneously or lead to fetal
demise19. The severity of the fetal anemia is due to
three factors, namely increased turnover of fetal
red blood cells, rapidly expanding intravascular
volume,andtheinabilityoftheimmatureimmune
system to fight the viral infection. The resulting
decrease in fetal hemoglobin concentration and
hematocrit due to the anemia can lead to high-
output congestive heart failure causing fetal
circulatory compromise. Red blood cells are not
the only cell line that is affected by the virus.
Parvovirus B-19has also been known to infect
megakaryocytes, placental cells, fetal liver cells and
myocardial cells, but these cells are not thought to
harbor any infectious virus or suffer permanent
harm20–23.
CLINICAL FINDINGS OF ACTIVE
DISEASE
The clinical findings are collectively referred to as
erythema infectiosum. The different phases of the
diseasedescribedearlierwillhavedifferentfindings
on physical examination. The first phase of the
disease will have nonspecific findings, including
fever, malaise and other nonspecific viral
symptoms. The patient may also present with a
photosensitive erythematous rash on the face that
spares the nasal and periorbital zones. This appear-
ance gave rise to the term ‘slapped face’ syndrome.
A second phase that is purely clinical, with no
change in the immunoglobulins, can show a lacy,
erythematous maculopapular exanthem on the
trunk and extremities. The rash may itch, but if
no itch is noted the diagnosis of parvovirus B-19
cannot be ruled out. The rashes will all usually
resolve within 7 to 10 days.
In 60% of adults and 10% of children infected
with parvovirus B-19, arthralgia/arthritis can be
seen. Painful, swollen and stiff joints characterize
this arthralgia. The most commonly affected joints
are the wrist, hand, knee and ankle. This arthralgia
usually lasts for 1 to 3 weeks, although rarely it can
last for months to years10–12.
SCREENING AND DIAGNOSIS
The virus can usually be recognized by the clinical
symptoms. In the adult this may sometimes be
difficult, as other adult viruses may present very
similarly. The diagnosis is made on the basis of
clinical findings, and is confirmed by a serological
test. An enzyme-linked immunosorbent assay
(ELISA) can be undertaken to look for maternal
antibodies23.
Circulating IgM suggests the presence of an
active infection, can be detected approximately
10 days after infection, and may remain positive
for up to 6 months. IgG antibodies, which suggest
a previous infection, are formed approximately
3 weeks after infection and may last for several
years or even for life24,25.
Maternal testing for parvovirus is not routinely
performed for all pregnant women. To test a fetus
for possible infection, a polymerase chain reaction
(PCR) is performed on a sample of the amniotic
fluid, as this test has a sensitivity greater than 97%
and a specificity of 79–99%28. An additional
option, namely obtaining a fetal cord blood
sample,isnotwidelyusedbecauseoftheassociated
1%fetallossrate,andalsobecausetheIgMdoesnot
often appear in the fetal circulation until after
22 weeks’ gestation. Postpartum testing of the
infant can be performed by a PCR on the bone
marrow, but not by serology. This is because
infants with congenital infection do not have virus
particles circulating in the blood, and the virus can
only be found in the bone marrow27–29.
MANAGEMENT/TREATMENT
Treatment of a parvovirus B-19infection is
dependentonthegestationalageofthefetus.Ifthe
mother tests positive for IgM and negative for IgG
(suggesting a new infection) at less than 20 weeks’
gestation,notreatmentisnecessary.Thisisbecause
B-19infection is associated with a very low risk of
congenital anomalies19. These patients should
undergoserialultrasoundexaminationstomonitor
for the development of fetal hydrops. It is
suggested that these ultrasound examinations be
performed at weekly intervals, but there is some
controversy over the necessity for repeated
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infectionoccursbefore20weeks’gestation,reach-
ing approximately 10%, and it declines rapidly as
the fetus ages30. Routine prenatal screening for
parvovirus B19is not advised. However, a woman
may be tested if she develops symptoms suggestive
of B-19 with a positive contact history.
Ifthefetusshowsevidenceofhydrops,themain
treatment option is intrauterine blood transfusion
to correct the associated anemia19. Testing of the
middle cerebral artery is the most sensitive,
noninvasivetestforintrauterineanemia31.Thistest
can be used as a diagnostic and screening tool to
monitor intrauterine (hemolysis/anemia) insult32.
If severe intrauterine hydrops/anemia is diagnosed
atagestationalageofmorethan28 weeks,delivery
and extrauterine treatment and management
should be considered. If the diagnosis is made at a
gestational age of less than 28 weeks, an intra-
uterine blood transfusion should be considered,
either intra-abdominally or by percutaneous
umbilical blood sampling (PUBS)16,17. This treat-
ment is also controversial, as it has been shown in
some case reports that hydrops may resolve
spontaneously without intervention33,34. There-
forecarefulpatientselectionandcounselingshould
be performed prior to administering aggressive
intrauterine therapy.
Termination of pregnancy is not indicated
because there is no increase in the incidence of
congenital malformations associated with acute
infection19,35,36.
If the pregnant woman tests positive for
parvovirus B-19, she should be informed of the
possible outcomes. During epidemic periods in
specific schools, infection rates may be 5–20-fold
higher, so avoiding potential infectious contacts,
serological testing, or both may occasionally be
appropriate34,37,38. Obstetricians may tailor their
recommendations to individual patients.
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